Progyny (NASDAQ:PGNY) Given Hold (C-) Rating at Weiss Ratings

Progyny (NASDAQ:PGNY - Get Free Report)'s stock had its "hold (c-)" rating reaffirmed by equities researchers at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

Several other research firms have also commented on PGNY. Raymond James Financial set a $28.00 price target on Progyny in a report on Friday, August 8th. Leerink Partnrs upgraded Progyny from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 8th. JPMorgan Chase & Co. lifted their price target on Progyny from $23.00 to $25.00 and gave the stock a "neutral" rating in a report on Tuesday, August 26th. Truist Financial lifted their price target on Progyny from $24.00 to $27.00 and gave the stock a "hold" rating in a report on Thursday, July 17th. Finally, Leerink Partners upgraded Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price target on the stock in a report on Tuesday, July 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $25.44.

Progyny Stock Down 0.1%

Shares of PGNY opened at $19.49 on Friday. Progyny has a 52-week low of $13.39 and a 52-week high of $26.76. The firm's fifty day moving average is $21.71 and its two-hundred day moving average is $22.04. The stock has a market cap of $1.68 billion, a PE ratio of 33.03, a price-to-earnings-growth ratio of 1.66 and a beta of 1.34.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.23). Progyny had a return on equity of 10.69% and a net margin of 4.28%.The business had revenue of $332.87 million for the quarter, compared to analyst estimates of $315.70 million. During the same period last year, the firm earned $0.17 EPS. The company's revenue for the quarter was up 9.5% compared to the same quarter last year. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. As a group, research analysts anticipate that Progyny will post 0.6 earnings per share for the current year.

Insider Transactions at Progyny

In other Progyny news, EVP Allison Swartz sold 2,398 shares of the business's stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $22.96, for a total transaction of $55,058.08. Following the sale, the executive vice president directly owned 79,697 shares in the company, valued at $1,829,843.12. This represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kevin K. Gordon sold 2,500 shares of the business's stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $22.04, for a total transaction of $55,100.00. Following the sale, the director owned 12,501 shares in the company, valued at $275,522.04. This trade represents a 16.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 7,895 shares of company stock worth $179,311 over the last quarter. Insiders own 9.40% of the company's stock.

Institutional Trading of Progyny

Institutional investors and hedge funds have recently bought and sold shares of the business. Cetera Trust Company N.A increased its stake in Progyny by 303.1% during the second quarter. Cetera Trust Company N.A now owns 1,310 shares of the company's stock worth $29,000 after purchasing an additional 985 shares during the period. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Progyny during the first quarter worth about $44,000. Militia Capital Partners LP increased its stake in Progyny by 100.0% during the first quarter. Militia Capital Partners LP now owns 2,000 shares of the company's stock worth $45,000 after purchasing an additional 1,000 shares during the period. Brooklyn Investment Group increased its stake in Progyny by 5,216.4% during the first quarter. Brooklyn Investment Group now owns 3,243 shares of the company's stock worth $72,000 after purchasing an additional 3,182 shares during the period. Finally, Canada Pension Plan Investment Board purchased a new stake in Progyny during the second quarter worth about $77,000. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.